HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time frames. The robust performance is primarily due to heightened demand for generic drugs and recent FDA approvals. Investors are advised to steer clear of merely chasing past successes and instead focus on a sustainable long-term strategy.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.